AUTHORS
Piyanuch Kongtim, MD, PhD, Pongthep Vittayawacharin, MD2, Piyatida Chumnumsiriwath, MD3, Anastasia Chumakova, MD4, Michael Sy, MD5, Stefan Ciurea, MD6
AFFILIATIONS
1 University of California Irvine, ORANGE, California, United States
2 University of California Irvine, ORANGE, California, United States
3 University of California Irvine, ORANGE, California, United States
4 University of California Irvine, ORANGE, California, United States
5 University of California Irvine, ORANGE, California, United States
6 University of California Irvine, ORANGE, California, United States
ABSTRACT
Background: Autologous stem cell transplantation (ASCT) offers the potential for durable disease control in patients with autoimmune diseases (AIDs) by resetting the immune system and eliminating antibodies generated against recipient’s tissues. Historically, however, its adoption has been limited as high-intensity conditioning carries significant toxicity risks, while non-myeloablative regimens may be associated with higher relapse. To address these limitations, our group developed a new reduced-intensity conditioning (RIC) regimen, Lite-BEAM-R, by modifying the standard BEAM protocol and incorporating rituximab for enhanced B-cell depletion. We hypothesized that Lite-BEAM-R would optimize tolerability while maximizing long-term disease control. Here, we report the outcomes of the first cohort of patients with AIDs treated with this regimen at our institution.
Methods: The cohort included adult patients (≥18 years) with severe, treatment-refractory AIDs receiving ASCT, for whom data were collected prospectively. Peripheral blood stem cells were mobilized using cyclophosphamide and G-CSF. All patients received the Lite-BEAM-R conditioning regimen: BCNU 300 mg/m² (Day -6), etoposide 100 mg/m² and cytarabine 100 mg/m² every 12 hours (Day -5 to -2), melphalan 100 mg/m² (Day -1), and rituximab 375 mg/m² (Days +1 and +8). Primary endpoints were safety and efficacy, including overall survival (OS), progression-free survival (PFS), and treatment-related mortality (TRM). For the MS cohort, neurological disability was longitudinally assessed using the Expanded Disability Status Scale (EDSS) with additional monitoring using the Octave MS Disease Activity (MSDA) score. Therapeutic success was further defined by the achievement of "No Evidence of Disease Activity" (NEDA-3), a composite endpoint of no clinical relapses, no sustained disability progression, and no new radiologic activity.
Results: A total of 30 consecutively treated patients (median age 46 years, range 23–74; 60% female) were included in this analysis. The cohort primarily consisted of MS patients (n=24; 80%), either RRMS (53.3%), PPMS (20%), or SPMS (6.67%), other patients had stiff person syndrome (SPS; n=2), scleroderma (n=1), CIDP (n=1), SLE (N=1), and myasthenia gravis (MG; n=1).
Median time from diagnosis to ASCT was 7.2 years (range 1-17), with a median of 3 (range 0-6) prior lines of disease-modifying therapies (DMTs) for MS patients. Indications for transplant in the MS cohort included DMT failure (70.8%), DMT contraindication/intolerance (16.7%). Notably, 12.5% (n=3) of MS patients were transplanted for relapse following prior ASCT (using Cy/ATG conditioning, N=2) or immune effector cell (IEC) therapy (N=1). MG patient had progressive disease after CAR-T cell therapy.
Hematologic recovery was prompt with median neutrophil engraftment of 11 days (range 10–20) and platelet engraftment of 12 days (range 7–25). Median hospitalization was 18 days (range 16-38). Manageable complications included febrile neutropenia (n=7, 22.6%), grade 1-2 mucositis (n=5), CVC-associated DVT (n=4), bacteremia (n=3), HHV6 reactivation (n=2), and engraftment syndrome (n=1). Median CD4+ counts rose from 283 cells/µL at 6 months to 395 cells/µL at 1 year. CD19+ B-cells were undetectable at 6 months but recovered to a median of 108 cells/µL by 1 year.
At a median follow-up of 421 days (52–1157), 3-year OS was 100% and PFS of 97%, with 0% TRM.
For patients with MS, radiographic stabilization was profound: no patients developed new T2 or T1 gadolinium-enhancing lesions at 6-month (N=19) or 1-year (N=14) post-transplant MRI. Median EDSS improved from 5 pre-ASCT (range 2-8) to 3 at 1 year post-ASCT (range, 0–8). An EDSS response (decrease of ≥1 point) at 6 months was achieved in 52.6% (6/19) of evaluable patients and 71.4% (10/14) at 1 year. All 14 patients with >1 year follow-up achieved NEDA-3 with median Octave MSDA score of 2 (range 0.5-3).
At 1 year, patient with scleroderma had no improvement in skin lesions, while patients with SPS and MG reported significant symptomatic improvement and 2 of 3 were able to return to work without further therapy.
Conclusion: ASCT with Lite-BEAM-R conditioning demonstrates excellent safety and efficacy for refractory AIDs, with sustained disease control associated with effective immune reset and B-cell depletion. ASCT should be considered early in the disease course to prevent progressive debilitation and irreversible end-organ damage.
DISCLOSURES
Piyanuch Kongtim, MD, PhD: CareDx - Consultancy (Includes expert testimony)